Compared to solid tumors, the number of mutations found in a given AML is much lower and several of them are druggable such as the FLT3 mutations as well as IDH1 and IDH2. Considering this, targeted therapies may be the ultimate weapon in the treatment of AMLs. The gene discussed is IDH1; the disease is acute myeloid leukemia.